Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Bio-Techne reported its third-quarter fiscal year 2025 results, exhibiting a strong performance despite navigating a challenging macroeconomic environment.</li><li>The company achieved 6% organic revenue growth, underscoring its resilience in the face of various uncertainties and highlighting the importance of its diversified product portfolio, including core reagents, automated analytical solutions, and cell and gene therapy offerings.</li><li>This growth was achieved while maintaining a robust adjusted operating margin of 34.9%, facilitated by strategic investments in operational efficiencies.</li></ul>

Bio-Techne reported its third-quarter fiscal year 2025 results, exhibiting a strong performance despite navigating a challenging macroeconomic environment.The company achieved 6% organic revenue growth, underscoring its resilience in the face of various uncertainties and highlighting the importance of its diversified product portfolio, including core reagents, automated analytical solutions, and cell and gene therapy offerings.This growth was achieved while maintaining a robust adjusted operating margin of 34.9%, facilitated by strategic investments in operational efficiencies.

Bio-Techne Corporation: An Insight Into The Pharmaceutical Market Dynamics & China's Economic & Regulatory Environment!

<ul><li>Bio-Techne Corporation's second quarter of fiscal year 2025 results showcased a blend of robust growth and some challenges.</li><li>The company reported a 9% year-over-year increase in revenue, achieving $297 million in total sales, which was also the growth rate on an organic basis.</li><li>This performance was largely fueled by significant contributions from the biopharma end markets, especially large pharmaceutical orders for Good Manufacturing Practice (GMP) reagents and protein analytical implementations, alongside notable strides in their ExosomeDx and spatial biology divisions.</li></ul>

Bio-Techne Corporation's second quarter of fiscal year 2025 results showcased a blend of robust growth and some challenges.The company reported a 9% year-over-year increase in revenue, achieving $297 million in total sales, which was also the growth rate on an organic basis.This performance was largely fueled by significant contributions from the biopharma end markets, especially large pharmaceutical orders for Good Manufacturing Practice (GMP) reagents and protein analytical implementations, alongside notable strides in their ExosomeDx and spatial biology divisions.

Bio-Techne Corporation: How Spatial Biology and Molecular Diagnostics Are Changing the Game!

<ul><li>Bio-Techne Corporation, a leading life sciences company, reported its financial results for the first quarter of Fiscal Year 2025.</li><li>With a 4% year-over-year organic revenue growth, the company demonstrated a solid performance, attributed to the stabilization of its biopharma end markets and robust execution in several areas, particularly in cell and gene therapy.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Bio-Techne Corporation, a leading life sciences company, reported its financial results for the first quarter of Fiscal Year 2025.With a 4% year-over-year organic revenue growth, the company demonstrated a solid performance, attributed to the stabilization of its biopharma end markets and robust execution in several areas, particularly in cell and gene therapy.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Bio-Techne Corporation: An Insight Into Its Market Position & Product Expansion in Diagnostics and Spatial Biology! - Major Drivers

<ul><li>Bio-Techne Corporation recently held its earnings call for the fourth quarter of fiscal year 2024, during which the company announced in-line financial results with modest organic revenue growth of 1% year-over-year.</li><li>This growth came amidst market stabilization and strategic execution by the company despite a complex external environment that included reduced biotech funding and significant budget recalibrations from large pharmaceutical entities and academia.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Bio-Techne Corporation recently held its earnings call for the fourth quarter of fiscal year 2024, during which the company announced in-line financial results with modest organic revenue growth of 1% year-over-year.This growth came amidst market stabilization and strategic execution by the company despite a complex external environment that included reduced biotech funding and significant budget recalibrations from large pharmaceutical entities and academia.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Bio-Techne Corporation: Enhanced Investment in Molecular Diagnostics

<ul><li>Bio-Techne Corporation, a biotech firm specializing in protein and cell-based research, recently reported their third quarter 2024 earnings.</li><li>The company displayed strong performance, and its financial circumstances seem to be stabilizing.</li><li>Bio-Techne's 2% year-over-year organic revenue growth exceeded their expectations, heralding potential expansion as biotech funding and macroeconomic challenges in China stabilize.</li></ul>

Bio-Techne Corporation, a biotech firm specializing in protein and cell-based research, recently reported their third quarter 2024 earnings.The company displayed strong performance, and its financial circumstances seem to be stabilizing.Bio-Techne's 2% year-over-year organic revenue growth exceeded their expectations, heralding potential expansion as biotech funding and macroeconomic challenges in China stabilize.

Bio-Techne Corporation: Growth in the Cell and Gene Therapy Market & Improved Positioning In Spatial Biology Market! - Major Drivers

United States

Bio-Techne Corp develops, manufactures and sells biotechnology products and clinical diagnostic controls. The Company specializes in proteins, cytokines, growth factors, immunoassays and small molecules.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bio Techne Corp (TECH US)

Bio-Techne Corporation: An Insight Into The Pharmaceutical Market Dynamics & China's Economic & Regulatory Environment!

Bio-Techne reported its third-quarter fiscal year 2025 results, exhibiting a strong performance despite navigating a challenging macroeconomic...

Baptista Research

Bio-Techne Corporation: How Spatial Biology and Molecular Diagnostics Are Changing the Game!

Bio-Techne Corporation's second quarter of fiscal year 2025 results showcased a blend of robust growth and some challenges. The company reported a...

Baptista Research

Bio-Techne Corporation: An Insight Into Its Market Position & Product Expansion in Diagnostics and Spatial Biology! - Major Drivers

Bio-Techne Corporation, a leading life sciences company, reported its financial results for the first quarter of Fiscal Year 2025. With a 4%...

Baptista Research

Bio-Techne Corporation: Enhanced Investment in Molecular Diagnostics

Bio-Techne Corporation recently held its earnings call for the fourth quarter of fiscal year 2024, during which the company announced in-line...

Baptista Research

Bio-Techne Corporation: Growth in the Cell and Gene Therapy Market & Improved Positioning In Spatial Biology Market! - Major Drivers

Bio-Techne Corporation, a biotech firm specializing in protein and cell-based research, recently reported their third quarter 2024 earnings. The...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)